請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/19906
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳佑宗 | |
dc.contributor.author | Chia-Cheng Hung | en |
dc.contributor.author | 洪加政 | zh_TW |
dc.date.accessioned | 2021-06-08T02:26:21Z | - |
dc.date.copyright | 2015-09-25 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-08-18 | |
dc.identifier.citation | 1. Alfarawati S, Fragouli E, Colls P, Wells D. First births after preimplantation genetic diagnosis of structural chromosome abnormalities using comparative genomic hybridization and microarray analysis. Hum Reprod. Jun 2011;26(6):1560-1574.
2. Lim CK, Cho JW, Song IO, Kang IS, Yoon YD, Jun JH. Estimation of chromosomal imbalances in preimplantation embryos from preimplantation genetic diagnosis cycles of reciprocal translocations with or without acrocentric chromosomes. Fertility and sterility. Dec 2008;90(6):2144-2151. 3. Fiorentino F, Spizzichino L, Bono S, et al. PGD for reciprocal and Robertsonian translocations using array comparative genomic hybridization. Hum Reprod. Jul 2011;26(7):1925-1935. 4. Keymolen K, Staessen C, Verpoest W, et al. A proposal for reproductive counselling in carriers of Robertsonian translocations: 10 years of experience with preimplantation genetic diagnosis. Hum Reprod. Sep 2009;24(9):2365-2371. 5. Chang LJ, Chen SU, Tsai YY, et al. An update of preimplantation genetic diagnosis in gene diseases, chromosomal translocation, and aneuploidy screening. Clinical and experimental reproductive medicine. Sep 2011;38(3):126-134. 6. Sermon K, Van Steirteghem A, Liebaers I. Preimplantation genetic diagnosis. Lancet. May 15 2004;363(9421):1633-1641. 7. Simpson JL. Preimplantation genetic diagnosis at 20 years. Prenatal diagnosis. Jul 2010;30(7):682-695. 8. Fischer J, Colls P, Escudero T, Munne S. Preimplantation genetic diagnosis (PGD) improves pregnancy outcome for translocation carriers with a history of recurrent losses. Fertility and sterility. Jun 2010;94(1):283-289. 9. Kokkali G, Traeger-Synodinos J, Vrettou C, et al. Blastocyst biopsy versus cleavage stage biopsy and blastocyst transfer for preimplantation genetic diagnosis of beta-thalassaemia: a pilot study. Hum Reprod. May 2007;22(5):1443-1449. 10. El-Toukhy T, Kamal A, Wharf E, et al. Reduction of the multiple pregnancy rate in a preimplantation genetic diagnosis programme after introduction of single blastocyst transfer and cryopreservation of blastocysts biopsied on day 3. Hum Reprod. Oct 2009;24(10):2642-2648. 11. Harper JC, Harton G. The use of arrays in preimplantation genetic diagnosis and screening. Fertility and sterility. Sep 2010;94(4):1173-1177. 12. Fiorentino F, Kokkali G, Biricik A, et al. Polymerase chain reaction-based detection of chromosomal imbalances on embryos: the evolution of preimplantation genetic diagnosis for chromosomal translocations. Fertility and sterility. Nov 2010;94(6):2001-2011, 2011 e2001-2006. 13. Fragouli E, Lenzi M, Ross R, Katz-Jaffe M, Schoolcraft WB, Wells D. Comprehensive molecular cytogenetic analysis of the human blastocyst stage. Hum Reprod. Nov 2008;23(11):2596-2608. 14. McArthur SJ, Leigh D, Marshall JT, Gee AJ, De Boer KA, Jansen RP. Blastocyst trophectoderm biopsy and preimplantation genetic diagnosis for familial monogenic disorders and chromosomal translocations. Prenatal diagnosis. May 2008;28(5):434-442. 15. Lee TH, Wu MY, Chen HF, Chen SU, Ho HN, Yang YS. Association of a single dose of gonadotropin-releasing hormone antagonist with nitric oxide and embryo quality in in vitro fertilization cycles. Fertility and sterility. Oct 2006;86(4):1020-1022. 16. Ho CH, Chen SU, Peng FS, Chang CY, Lien YR, Yang YS. Prospective comparison of short and long GnRH agonist protocols using recombinant gonadotrophins for IVF/ICSI treatments. Reproductive biomedicine online. May 2008;16(5):632-639. 17. Wu MY, Chang LJ, Chen MJ, Chao KH, Yang YS, Ho HN. Outcomes of assisted reproductive techniques for HIV-1-discordant couples using thawed washed sperm in Taiwan: comparison with control and testicular sperm extraction/microscopic epididymal sperm aspiration groups. Journal of the Formosan Medical Association = Taiwan yi zhi. Aug 2011;110(8):495-500. 18. Chen YL, Hung CC, Lin SY, et al. Successful application of the strategy of blastocyst biopsy, vitrification, whole genome amplification, and thawed embryo transfer for preimplantation genetic diagnosis of neurofibromatosis type 1. Taiwanese journal of obstetrics & gynecology. Mar 2011;50(1):74-78. 19. Chen SU, Lien YR, Chang LJ, Tsai YY, Ho HN, Yang YS. Cryopreserved sibling oocytes and intracytoplasmic sperm injection rescue unexpectedly poor fertilization in conventional in vitro fertilization. Journal of assisted reproduction and genetics. Oct 2004;21(10):367-369. 20. Goossens V, Harton G, Moutou C, Traeger-Synodinos J, Van Rij M, Harper JC. ESHRE PGD Consortium data collection IX: cycles from January to December 2006 with pregnancy follow-up to October 2007. Hum Reprod. Aug 2009;24(8):1786-1810. 21. Gianaroli L, Magli MC, Fiorentino F, Baldi M, Ferraretti AP. Clinical value of preimplantation genetic diagnosis. Placenta. Oct 2003;24 Suppl B:S77-83. 22. Munne S. Preimplantation genetic diagnosis for translocations. Hum Reprod. Mar 2006;21(3):839-840; author reply 840. 23. Verpoest W, Haentjens P, De Rycke M, et al. Cumulative reproductive outcome after preimplantation genetic diagnosis: a report on 1498 couples. Hum Reprod. Nov 2009;24(11):2951-2959. 24. Verlinsky Y, Tur-Kaspa I, Cieslak J, et al. Preimplantation testing for chromosomal disorders improves reproductive outcome of poor-prognosis patients. Reproductive biomedicine online. Aug 2005;11(2):219-225. 25. Johnson DS, Gemelos G, Baner J, et al. Preclinical validation of a microarray method for full molecular karyotyping of blastomeres in a 24-h protocol. Hum Reprod. Apr 2010;25(4):1066-1075. 26. Gutierrez-Mateo C, Colls P, Sanchez-Garcia J, et al. Validation of microarray comparative genomic hybridization for comprehensive chromosome analysis of embryos. Fertility and sterility. Mar 1 2011;95(3):953-958. 27. Vanneste E, Melotte C, Voet T, et al. PGD for a complex chromosomal rearrangement by array comparative genomic hybridization. Hum Reprod. Apr 2011;26(4):941-949. 28. Spits C, Sermon K. PGD for monogenic disorders: aspects of molecular biology. Prenatal diagnosis. Jan 2009;29(1):50-56. 29. Wilton L. Preimplantation genetic diagnosis and chromosome analysis of blastomeres using comparative genomic hybridization. Human reproduction update. Jan-Feb 2005;11(1):33-41. 30. Schoolcraft WB, Fragouli E, Stevens J, Munne S, Katz-Jaffe MG, Wells D. Clinical application of comprehensive chromosomal screening at the blastocyst stage. Fertility and sterility. Oct 2010;94(5):1700-1706. 31. Devroey P, Polyzos NP, Blockeel C. An OHSS-Free Clinic by segmentation of IVF treatment. Hum Reprod. Oct 2011;26(10):2593-2597. 32. Huang CC, Lien YR, Chen HF, et al. The duration of pre-ovulatory serum progesterone elevation before hCG administration affects the outcome of IVF/ICSI cycles. Hum Reprod. Jul 2012;27(7):2036-2045. 33. Prior TW. Carrier screening for spinal muscular atrophy. Genet Med. Nov 2008;10(11):840-842. 34. Ogino S, Wilson RB. Spinal muscular atrophy: molecular genetics and diagnostics. Expert Rev Mol Diagn. Jan 2004;4(1):15-29. 35. Lunn MR, Wang CH. Spinal muscular atrophy. Lancet. Jun 21 2008;371(9630):2120-2133. 36. Pearn J. Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J Med Genet. Dec 1978;15(6):409-413. 37. Pearn J. Classification of spinal muscular atrophies. Lancet. Apr 26 1980;1(8174):919-922. 38. Roe AM, Shur N. From new screens to discovered genes: the successful past and promising present of single gene disorders. Am J Med Genet C Semin Med Genet. Feb 15 2007;145C(1):77-86. 39. Lefebvre S, Burglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. Jan 13 1995;80(1):155-165. 40. Burglen L, Lefebvre S, Clermont O, et al. Structure and organization of the human survival motor neurone (SMN) gene. Genomics. Mar 15 1996;32(3):479-482. 41. Kashima T, Manley JL. A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. Nat Genet. Aug 2003;34(4):460-463. 42. Cartegni L, Krainer AR. Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat Genet. Apr 2002;30(4):377-384. 43. Wirth B, Herz M, Wetter A, et al. Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype-phenotype correlation, and implications for genetic counseling. Am J Hum Genet. May 1999;64(5):1340-1356. 44. Mailman MD, Heinz JW, Papp AC, et al. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med. Jan-Feb 2002;4(1):20-26. 45. Prior TW, Swoboda KJ, Scott HD, Hejmanowski AQ. Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2. Am J Med Genet A. Oct 15 2004;130A(3):307-310. 46. Kaback MM. Population-based genetic screening for reproductive counseling: the Tay-Sachs disease model. Eur J Pediatr. Dec 2000;159 Suppl 3:S192-195. 47. Kronn D, Jansen V, Ostrer H. Carrier screening for cystic fibrosis, Gaucher disease, and Tay-Sachs disease in the Ashkenazi Jewish population: the first 1000 cases at New York University Medical Center, New York, NY. Arch Intern Med. Apr 13 1998;158(7):777-781. 48. Zuckerman S, Lahad A, Shmueli A, et al. Carrier screening for Gaucher disease: lessons for low-penetrance, treatable diseases. JAMA. Sep 19 2007;298(11):1281-1290. 49. Norton ME. Genetic screening and counseling. Curr Opin Obstet Gynecol. Apr 2008;20(2):157-163. 50. Anhuf D, Eggermann T, Rudnik-Schoneborn S, Zerres K. Determination of SMN1 and SMN2 copy number using TaqMan technology. Hum Mutat. Jul 2003;22(1):74-78. 51. Cusco I, Barcelo MJ, Baiget M, Tizzano EF. Implementation of SMA carrier testing in genetic laboratories: comparison of two methods for quantifying the SMN1 gene. Hum Mutat. Dec 2002;20(6):452-459. 52. Arkblad EL, Darin N, Berg K, et al. Multiplex ligation-dependent probe amplification improves diagnostics in spinal muscular atrophy. Neuromuscul Disord. Dec 2006;16(12):830-838. 53. Basel-Vanagaite L, Taub E, Drasinover V, et al. Genetic carrier screening for spinal muscular atrophy and spinal muscular atrophy with respiratory distress 1 in an isolated population in Israel. Genet Test. Mar 2008;12(1):53-56. 54. Arkblad E, Tulinius M, Kroksmark AK, Henricsson M, Darin N. A population-based study of genotypic and phenotypic variability in children with spinal muscular atrophy. Acta Paediatr. Jan 20 2009. 55. Hendrickson BC, Donohoe C, Akmaev VR, et al. Differences in SMN1 allele frequencies among ethnic groups within North America. J Med Genet. Sep 2009;46(9):641-644. 56. Lee TM, Kim SW, Lee KS, et al. Quantitative analysis of SMN1 gene and estimation of SMN1 deletion carrier frequency in Korean population based on real-time PCR. J Korean Med Sci. Dec 2004;19(6):870-873. 57. Smith M, Calabro V, Chong B, Gardiner N, Cowie S, du Sart D. Population screening and cascade testing for carriers of SMA. Eur J Hum Genet. Jul 2007;15(7):759-766. 58. Su YN, Hung CC, Li H, et al. Quantitative analysis of SMN1 and SMN2 genes based on DHPLC: a highly efficient and reliable carrier-screening test. Hum Mutat. May 2005;25(5):460-467. 59. Hung CC, Lee CN, Chen CP, et al. Quantification of relative gene dosage by single-base extension and high-performance liquid chromatography: application to the SMN1/SMN2 gene. Anal Chem. Nov 1 2005;77(21):6960-6968. 60. Campbell L, Potter A, Ignatius J, Dubowitz V, Davies K. Genomic variation and gene conversion in spinal muscular atrophy: implications for disease process and clinical phenotype. Am J Hum Genet. Jul 1997;61(1):40-50. 61. McAndrew PE, Parsons DW, Simard LR, et al. Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number. Am J Hum Genet. Jun 1997;60(6):1411-1422. 62. Ogino S, Wilson RB, Gold B. New insights on the evolution of the SMN1 and SMN2 region: simulation and meta-analysis for allele and haplotype frequency calculations. Eur J Hum Genet. Dec 2004;12(12):1015-1023. 63. Wang CH, Finkel RS, Bertini ES, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. Aug 2007;22(8):1027-1049. 64. Cusin V, Clermont O, Gerard B, Chantereau D, Elion J. Prevalence of SMN1 deletion and duplication in carrier and normal populations: implication for genetic counselling. J Med Genet. Apr 2003;40(4):e39. 65. Feldkotter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet. Feb 2002;70(2):358-368. 66. Ogino S, Wilson RB. Genetic testing and risk assessment for spinal muscular atrophy (SMA). Hum Genet. Dec 2002;111(6):477-500. 67. ACOG committee opinion No. 432: spinal muscular atrophy. Obstet Gynecol. May 2009;113(5):1194-1196. 68. Chan V, Yip B, Yam I, et al. Carrier incidence for spinal muscular atrophy in southern Chinese. J Neurol. Sep 2004;251(9):1089-1093. 69. Ogino S, Leonard DG, Rennert H, Ewens WJ, Wilson RB. Genetic risk assessment in carrier testing for spinal muscular atrophy. Am J Med Genet. Jul 15 2002;110(4):301-307. 70. Wirth B, Schmidt T, Hahnen E, et al. De novo rearrangements found in 2% of index patients with spinal muscular atrophy: mutational mechanisms, parental origin, mutation rate, and implications for genetic counseling. Am J Hum Genet. Nov 1997;61(5):1102-1111. 71. Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat. 2000;15(3):228-237. 72. Oprea GE, Krober S, McWhorter ML, et al. Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science. Apr 25 2008;320(5875):524-527. 73. Jedrzejowska M, Borkowska J, Zimowski J, et al. Unaffected patients with a homozygous absence of the SMN1 gene. Eur J Hum Genet. Aug 2008;16(8):930-934. 74. Burlet P, Huber C, Bertrandy S, et al. The distribution of SMN protein complex in human fetal tissues and its alteration in spinal muscular atrophy. Hum Mol Genet. Nov 1998;7(12):1927-1933. 75. Jablonka S, Bandilla M, Wiese S, et al. Co-regulation of survival of motor neuron (SMN) protein and its interactor SIP1 during development and in spinal muscular atrophy. Hum Mol Genet. Mar 1 2001;10(5):497-505. 76. Pagliardini S, Giavazzi A, Setola V, et al. Subcellular localization and axonal transport of the survival motor neuron (SMN) protein in the developing rat spinal cord. Hum Mol Genet. Jan 1 2000;9(1):47-56. 77. Gavrilov DK, Shi X, Das K, Gilliam TC, Wang CH. Differential SMN2 expression associated with SMA severity. Nat Genet. Nov 1998;20(3):230-231. 78. Lefebvre S, Burlet P, Liu Q, et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet. Jul 1997;16(3):265-269. 79. Ben-Shachar S, Orr-Urtreger A, Bardugo E, Shomrat R, Yaron Y. Large-scale population screening for spinal muscular atrophy: Clinical implications. Genet Med. Jan 12 2011. 80. Muralidharan K, Wilson RB, Ogino S, Nagan N, Curtis C, Schrijver I. Population carrier screening for spinal muscular atrophy a position statement of the association for molecular pathology. J Mol Diagn. Jan 2011;13(1):3-6. 81. Prior TW, Snyder PJ, Rink BD, et al. Newborn and carrier screening for spinal muscular atrophy. Am J Med Genet A. Jul 2010;152A(7):1608-1616. 82. Prior TW. Spinal muscular atrophy: newborn and carrier screening. Obstet Gynecol Clin North Am. Mar 2010;37(1):23-36, Table of Contents. 83. Scarciolla O, Stuppia L, De Angelis MV, et al. Spinal muscular atrophy genotyping by gene dosage using multiple ligation-dependent probe amplification. Neurogenetics. Nov 2006;7(4):269-276. 84. Gerard B, Ginet N, Matthijs G, et al. Genotype determination at the survival motor neuron locus in a normal population and SMA carriers using competitive PCR and primer extension. Hum Mutat. Sep 2000;16(3):253-263. 85. Saugier-Veber P, Drouot N, Lefebvre S, et al. Detection of heterozygous SMN1 deletions in SMA families using a simple fluorescent multiplex PCR method. J Med Genet. Apr 2001;38(4):240-243. 86. Dreesen JC, Bras M, de Die-Smulders C, et al. Preimplantation genetic diagnosis of spinal muscular atrophy. Mol Hum Reprod. Sep 1998;4(9):881-885. 87. Moutou C, Gardes N, Rongieres C, et al. Allele-specific amplification for preimplantation genetic diagnosis (PGD) of spinal muscular atrophy. Prenat Diagn. Jun 2001;21(6):498-503. 88. Daniels G, Pettigrew R, Thornhill A, et al. Six unaffected livebirths following preimplantation diagnosis for spinal muscular atrophy. Mol Hum Reprod. Oct 2001;7(10):995-1000. 89. Burlet P, Frydman N, Gigarel N, et al. Improved single-cell protocol for preimplantation genetic diagnosis of spinal muscular atrophy. Fertil Steril. Sep 2005;84(3):734-739. 90. Moutou C, Machev N, Gardes N, Viville S. Case report: birth after preimplantation genetic diagnosis of a subtle mutation in SMN1 gene. Prenat Diagn. Nov 2006;26(11):1037-1041. 91. Moutou C, Gardes N, Viville S. Duplex PCR for preimplantation genetic diagnosis (PGD) of spinal muscular atrophy. Prenat Diagn. Aug 2003;23(8):685-689. 92. Girardet A, Fernandez C, Claustres M. Efficient strategies for preimplantation genetic diagnosis of spinal muscular atrophy. Fertil Steril. Aug 2008;90(2):443 e447-412. 93. Malcov M, Schwartz T, Mei-Raz N, et al. Multiplex nested PCR for preimplantation genetic diagnosis of spinal muscular atrophy. Fetal Diagn Ther. Mar-Apr 2004;19(2):199-206. 94. Blake D, Tan SL, Ao A. Assessment of multiplex fluorescent PCR for screening single cells for trisomy 21 and single gene defects. Mol Hum Reprod. Dec 1999;5(12):1166-1175. 95. Coskun S, Alsmadi O. Whole genome amplification from a single cell: a new era for preimplantation genetic diagnosis. Prenat Diagn. Apr 2007;27(4):297-302. 96. Wells D, Sherlock JK. Strategies for preimplantation genetic diagnosis of single gene disorders by DNA amplification. Prenat Diagn. Dec 1998;18(13):1389-1401. 97. Burlet P, Gigarel N, Magen M, et al. Single-sperm analysis for recurrence risk assessment of spinal muscular atrophy. Eur J Hum Genet. Apr 2010;18(4):505-508. 98. Monani UR, Lorson CL, Parsons DW, et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet. Jul 1999;8(7):1177-1183. 99. Hung CC, Chen SU, Lin SY, et al. Preimplantation genetic diagnosis of beta-thalassemia using real-time polymerase chain reaction with fluorescence resonance energy transfer hybridization probes. Anal Biochem. May 1 2010;400(1):69-77. 100. Kennedy CR, McCann DC, Campbell MJ, et al. Language ability after early detection of permanent childhood hearing impairment. The New England journal of medicine. May 18 2006;354(20):2131-2141. 101. Thompson DC, McPhillips H, Davis RL, Lieu TL, Homer CJ, Helfand M. Universal newborn hearing screening: summary of evidence. Jama. Oct 24-31 2001;286(16):2000-2010. 102. Wake M, Tobin S, Cone-Wesson B, et al. Slight/mild sensorineural hearing loss in children. Pediatrics. Nov 2006;118(5):1842-1851. 103. Yoshinaga-Itano C, Sedey AL, Coulter DK, Mehl AL. Language of early- and later-identified children with hearing loss. Pediatrics. Nov 1998;102(5):1161-1171. 104. Controlled trial of universal neonatal screening for early identification of permanent childhood hearing impairment. Wessex Universal Neonatal Hearing Screening Trial Group. Lancet. Dec 19-26 1998;352(9145):1957-1964. 105. Kennedy C, McCann D, Campbell MJ, Kimm L, Thornton R. Universal newborn screening for permanent childhood hearing impairment: an 8-year follow-up of a controlled trial. Lancet. Aug 20-26 2005;366(9486):660-662. 106. Barsky-Firkser L, Sun S. Universal newborn hearing screenings: a three-year experience. Pediatrics. Jun 1997;99(6):E4. 107. Vohr BR, Carty LM, Moore PE, Letourneau K. The Rhode Island Hearing Assessment Program: experience with statewide hearing screening (1993-1996). The Journal of pediatrics. Sep 1998;133(3):353-357. 108. Mason JA, Herrmann KR. Universal infant hearing screening by automated auditory brainstem response measurement. Pediatrics. Feb 1998;101(2):221-228. 109. Johnson JL, White KR, Widen JE, et al. A multicenter evaluation of how many infants with permanent hearing loss pass a two-stage otoacoustic emissions/automated auditory brainstem response newborn hearing screening protocol. Pediatrics. Sep 2005;116(3):663-672. 110. White KR, Forsman I, Eichwald J, Munoz K. The evolution of early hearing detection and intervention programs in the United States. Seminars in perinatology. Apr 2010;34(2):170-179. 111. Smith RJ. Snapshots of cAMP david. Science. Jul 27 1979;205(4404):379. 112. Hilgert N, Smith RJ, Van Camp G. Forty-six genes causing nonsyndromic hearing impairment: which ones should be analyzed in DNA diagnostics? Mutation research. Mar-Jun 2009;681(2-3):189-196. 113. Snoeckx RL, Huygen PL, Feldmann D, et al. GJB2 mutations and degree of hearing loss: a multicenter study. American journal of human genetics. Dec 2005;77(6):945-957. 114. Everett LA, Glaser B, Beck JC, et al. Pendred syndrome is caused by mutations in a putative sulphate transporter gene (PDS). Nature genetics. Dec 1997;17(4):411-422. 115. Li XC, Everett LA, Lalwani AK, et al. A mutation in PDS causes non-syndromic recessive deafness. Nature genetics. Mar 1998;18(3):215-217. 116. Mori T, Westerberg BD, Atashband S, Kozak FK. Natural history of hearing loss in children with enlarged vestibular aqueduct syndrome. Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale. Feb 2008;37(1):112-118. 117. Kokotas H, Petersen MB, Willems PJ. Mitochondrial deafness. Clinical genetics. May 2007;71(5):379-391. 118. Chang KW, Vohr BR, Norton SJ, Lekas MD. External and middle ear status related to evoked otoacoustic emission in neonates. Archives of otolaryngology--head & neck surgery. Mar 1993;119(3):276-282. 119. Wu CC, Chen PJ, Chiu YH, Lu YC, Wu MC, Hsu CJ. Prospective mutation screening of three common deafness genes in a large Taiwanese Cohort with idiopathic bilateral sensorineural hearing impairment reveals a difference in the results between families from hospitals and those from rehabilitation facilities. Audiology & neuro-otology. 2008;13(3):172-181. 120. Wu CC, Lu YC, Chen PJ, Liu AY, Hwu WL, Hsu CJ. Application of SNaPshot multiplex assays for simultaneous multigene mutation screening in patients with idiopathic sensorineural hearing impairment. The Laryngoscope. Dec 2009;119(12):2411-2416. 121. Hwa HL, Ko TM, Hsu CJ, et al. Mutation spectrum of the connexin 26 (GJB2) gene in Taiwanese patients with prelingual deafness. Genetics in medicine : official journal of the American College of Medical Genetics. May-Jun 2003;5(3):161-165. 122. Jackler RK, De La Cruz A. The large vestibular aqueduct syndrome. The Laryngoscope. Dec 1989;99(12):1238-1242; discussion 1242-1233. 123. Chan DK, Schrijver I, Chang KW. Connexin-26-associated deafness: phenotypic variability and progression of hearing loss. Genetics in medicine : official journal of the American College of Medical Genetics. Mar 2010;12(3):174-181. 124. Kennedy C, Kimm L, Thornton R, Davis A. False positives in universal neonatal screening for permanent childhood hearing impairment. Lancet. Dec 2 2000;356(9245):1903-1904. 125. Bess FH, Dodd-Murphy J, Parker RA. Children with minimal sensorineural hearing loss: prevalence, educational performance, and functional status. Ear and hearing. Oct 1998;19(5):339-354. 126. Hick CB, Tharpe AM. Listening effort and fatigue in school-age children with and without hearing loss. Journal of speech, language, and hearing research : JSLHR. Jun 2002;45(3):573-584. 127. Davis JM, Elfenbein J, Schum R, Bentler RA. Effects of mild and moderate hearing impairments on language, educational, and psychosocial behavior of children. The Journal of speech and hearing disorders. Feb 1986;51(1):53-62. 128. Cone BK, Wake M, Tobin S, Poulakis Z, Rickards FW. Slight-mild sensorineural hearing loss in children: audiometric, clinical, and risk factor profiles. Ear and hearing. Apr 2010;31(2):202-212. 129. McKay S, Gravel JS, Tharpe AM. Amplification considerations for children with minimal or mild bilateral hearing loss and unilateral hearing loss. Trends in amplification. Mar 2008;12(1):43-54. 130. Tsukada K, Nishio S, Usami S. A large cohort study of GJB2 mutations in Japanese hearing loss patients. Clinical genetics. Nov 2010;78(5):464-470. 131. Wu CC, Chiu YH, Chen PJ, Hsu CJ. Prevalence and clinical features of the mitochondrial m.1555A>G mutation in Taiwanese patients with idiopathic sensorineural hearing loss and association of haplogroup F with low penetrance in three families. Ear and hearing. Jun 2007;28(3):332-342. 132. Young NM, Reilly BK, Burke L. Limitations of universal newborn hearing screening in early identification of pediatric cochlear implant candidates. Archives of otolaryngology--head & neck surgery. Mar 2011;137(3):230-234. 133. Dhondt JL. Expanded newborn screening: social and ethical issues. Journal of inherited metabolic disease. Oct 2010;33(Suppl 2):S211-217. 134. Levy N. Deafness, culture, and choice. Journal of medical ethics. Oct 2002;28(5):284-285. 135. Withrow KA, Burton S, Arnos KS, Kalfoglou A, Pandya A. Consumer motivations for pursuing genetic testing and their preferences for the provision of genetic services for hearing loss. Journal of genetic counseling. Jun 2008;17(3):252-260. 136. Lewis S, Curnow L, Ross M, Massie J. Parental attitudes to the identification of their infants as carriers of cystic fibrosis by newborn screening. Journal of paediatrics and child health. Sep 2006;42(9):533-537. 137. Lipan M, Ouyang X, Yan D, Angeli S, Du LL, Liu XZ. Clinical comparison of hearing-impaired patients with DFNB1 against heterozygote carriers of connexin 26 mutations. The Laryngoscope. Apr 2011;121(4):811-814. 138. Morell RJ, Kim HJ, Hood LJ, et al. Mutations in the connexin 26 gene (GJB2) among Ashkenazi Jews with nonsyndromic recessive deafness. The New England journal of medicine. Nov 19 1998;339(21):1500-1505. 139. Batsakis JG, Nishiyama RH. Deafness with sporadic goiter. Pendred's syndrome. Arch Otolaryngol. Nov 1962;76:401-406. 140. Tsukamoto K, Suzuki H, Harada D, Namba A, Abe S, Usami S. Distribution and frequencies of PDS (SLC26A4) mutations in Pendred syndrome and nonsyndromic hearing loss associated with enlarged vestibular aqueduct: a unique spectrum of mutations in Japanese. European journal of human genetics : EJHG. Dec 2003;11(12):916-922. 141. Park HJ, Shaukat S, Liu XZ, et al. Origins and frequencies of SLC26A4 (PDS) mutations in east and south Asians: global implications for the epidemiology of deafness. Journal of medical genetics. Apr 2003;40(4):242-248. 142. Hutchin TP, Thompson KR, Parker M, Newton V, Bitner-Glindzicz M, Mueller RF. Prevalence of mitochondrial DNA mutations in childhood/congenital onset non-syndromal sensorineural hearing impairment. Journal of medical genetics. Apr 2001;38(4):229-231. 143. Kupka S, Toth T, Wrobel M, et al. Mutation A1555G in the 12S rRNA gene and its epidemiological importance in German, Hungarian, and Polish patients. Human mutation. Mar 2002;19(3):308-309. 144. Usami S, Abe S, Akita J, et al. Prevalence of mitochondrial gene mutations among hearing impaired patients. Journal of medical genetics. Jan 2000;37(1):38-40. 145. Malik SG, Pieter N, Sudoyo H, Kadir A, Marzuki S. Prevalence of the mitochondrial DNA A1555G mutation in sensorineural deafness patients in island Southeast Asia. Journal of human genetics. 2003;48(9):480-483. 146. Migliosi V, Modamio-Hoybjor S, Moreno-Pelayo MA, et al. Q829X, a novel mutation in the gene encoding otoferlin (OTOF), is frequently found in Spanish patients with prelingual non-syndromic hearing loss. Journal of medical genetics. Jul 2002;39(7):502-506. 147. Shearer AE, DeLuca AP, Hildebrand MS, et al. Comprehensive genetic testing for hereditary hearing loss using massively parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America. Dec 7 2010;107(49):21104-21109. 148. Del Castillo I, Moreno-Pelayo MA, Del Castillo FJ, et al. Prevalence and evolutionary origins of the del(GJB6-D13S1830) mutation in the DFNB1 locus in hearing-impaired subjects: a multicenter study. American journal of human genetics. Dec 2003;73(6):1452-1458. 149. Norris VW, Arnos KS, Hanks WD, Xia X, Nance WE, Pandya A. Does universal newborn hearing screening identify all children with GJB2 (Connexin 26) deafness? Penetrance of GJB2 deafness. Ear and hearing. Dec 2006;27(6):732-741. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/19906 | - |
dc.description.abstract | 研究目的
隨著基因診斷技術的快速發展,近幾年來有愈來愈多的遺傳性疾病被證實與單一基因變異有關。因此,基因檢測就變得非常重要,可以提供個人基因或是染色體的資訊。目前常見的基因檢測有產前篩檢、帶因者篩檢、胚胎著床前檢測、法醫檢測與新生兒檢測等。然而因為要建立一套標準的基因檢測流程並不容易,所以台灣目前的基因篩檢,仍然侷限於傳統的產前染色體檢查與新生兒先天代謝性與內分泌性疾病基因篩檢等,對於部分普及的基因檢測則仍欠缺。所以如何建立最新的基因篩檢流程並於應用於臨床,成了刻不容緩的重要課題。 研究方法 第一部分:胚胎著床前基因診斷於染色體轉位之應用 本研究收集自2011年至2014年, 46對在第一孕期或第二孕期習慣性與自發性重複流產的夫妻,且夫妻其中一方帶有染色體結構平衡性異常。個案在台灣各地人工生殖中心經過醫師與遺傳諮詢師討論後,接受試管嬰兒療程並執行胚胎著床前基因診斷。這期間總共執行76個週期、365個胚胎切片,利用微陣列比較式基因體雜交分析技術進行胚胎著床前基因診斷。 第二部分:脊髓性肌肉萎縮症帶因者篩檢 本研究為大規模前瞻性的世代人群研究,自2005年至2014年,共10年的時間從台灣25縣市收集139,404位懷孕婦女檢體。利用雙平台基因檢測技術,包括DNA 片段突變分析儀與多重連接探針擴增技術,進行SMN1/SMN2基因定量分析。此帶因者篩檢流程共分成三階段:(1)篩檢懷孕婦女是否為脊髓性肌肉萎縮症帶因者;(2) 若懷孕婦女為脊髓性肌肉萎縮症帶因者,則請配偶進行脊髓性肌肉萎縮症帶因者篩檢;(3) 若夫妻雙方皆為脊髓性肌肉萎縮症帶因者,則建議進行產前診斷。 第三部分:胚胎著床前基因診斷於脊髓性肌肉萎縮症之應用 針對一對雙方皆為脊髓性肌肉萎縮症帶因者的夫妻,利用囊胚期胚胎滋養層細胞切片、全基因體放大技術、微測序基因診斷技術與3個微衛星標記進行連鎖分析,針對1個週期、18個胚胎進行脊髓性肌肉萎縮症基因的胚胎著床前基因診斷,並選擇基因型正常的胚胎植入。 第四部分:遺傳性聽損新生兒基因檢測 本研究針對2011年至2014年於台灣各醫院診所出生的26,764位新生兒,並經由設計專一性引子對進行聚合酵素鏈鎖反應,利用螢光共振能量傳遞與即時核酸定量分析儀進行基因分析。根據台灣群族遺傳性聽損之基因檢體庫,進行常見的四個感覺神經性聽損基因突變點位之基因分析,四個突變點位分別為GJB2基因c.109G>A、GJB2基因c.235delC、SLC26A4基因c.919-2A>G與12S rRNA基因m.1555A>G。 結果 第一部分:胚胎著床前基因診斷於染色體轉位之應用 總共76個週期、365個胚胎進行基因診斷中,其胚胎成功放大率約為89.04% (325/365)。其中315個胚胎進行微陣列比較式基因體雜交分析,染色體劑量為整倍體的比例為26.67% (84/315),染色體劑量異常的比例為73.66% (231/315)。共有49個週期可提供胚胎植入,平均每個週期可提供植入胚胎為1.11 顆。後續追蹤32對夫妻52個週期,胚胎植入後有15位婦女成功受孕,治療週期懷孕率為28.85% (15/52)。 第二部分:脊髓性肌肉萎縮症帶因者篩檢 我們統計在139,404位懷孕婦女中,共有2,859位為脊髓性肌肉萎縮症帶因者,約每49個人就有一位是脊髓性肌肉萎縮症帶因者,帶因率為2.05%。其中共有2,504位帶因者的配偶回診進行基因篩檢,有58位男性配偶同樣為脊髓性肌肉萎縮症帶因者,帶因率約為 2.32%。這58個具有生下脊髓性肌肉萎縮症患者的高風險家庭中,有49位懷孕婦女進行產前診斷,且有13個胎兒診斷為脊髓性肌肉萎縮症患者。因此在我們研究的台灣族群中,脊髓性肌肉萎縮症的盛行率約為1/10,723。 第三部分:胚胎著床前基因診斷於脊髓性肌肉萎縮症之應用 在單一週期中,胚胎成功放大率約為77.78% (14/18),其中有10顆胚胎診斷為正常 (71.43%, 10/14),2顆胚胎為異常 (14.29%, 2/14),2顆胚胎因為實驗過程中等位基因遺失而造成無法判讀 (14.29%, 2/14)。後續選擇2個正常胚胎植入後成功受孕,並產下一位正常帶因者女孩。 第四部分:遺傳性聽損新生兒基因檢測 在26,764位新生兒中,共有5,253個新生兒 (19.63%) 具有至少一個聽損基因點位突變。總共399個新生兒 (1.49%) 帶有同型合子、複合性同型合子或同質體的基因突變,將有可能導致聽損。在這之中,298個新生兒 (1.11%) 為GJB2基因c.109 G>A同型合子,2個新生兒 (0.01%) 為GJB2基因c.235 delG同型合子、5個新生兒 (0.02%) 為SLC26A4基因c.919-2A>G同型合子、28個新生兒 (0.11%) 為GJB2基因c.109 G>A與c.235delC複合型同型合子,及66個新生兒 (0.25%) 為粒線體12S rRNA基因m.1555A>G同質體或異質體。 結論 在此我們建立四種嶄新的基因篩檢平台,包括胚胎著床前基因診斷於染色體轉位、脊髓性肌肉萎縮症帶因者篩檢、胚胎著床前基因診斷於單基因遺傳疾病及遺傳性聽損新生兒基因檢測。隨著新的基因診斷之不斷更新,檢驗技術成本逐漸降低,基因檢測將可以成為分子診斷的有力工具,期待這些檢測應用於臨床可以幫助更多病人及其家屬。 | zh_TW |
dc.description.abstract | Introduction
With the rapid development of genetic diagnostic technologies in recent years, there are more and more inherited diseases have been linked to single gene variation. Hence, the genetic testing is very important that can provide information about an individual’s genes or chromosomes. Recently, the common genetic tests include prenatal screening, carrier screening, preimplantation testing, forensic testing, newborn screening, and so on. However, because establishment of a standard protocol for genetic testing is not easy, the current genetic testing in Taiwan, still limited to traditional platforms, such as prenatal diagnosis by karyotyping and newborn screening for congenital metabolic and endocrine diseases. Some widespread genetic tests are still not available now. So, how to create the latest genetic screening protocol for clinical use has become an important issue without delay. Materials and Methods PART 1 Preimplantation genetic diagnosis for chromosomal translocation The study included 46 couples with recurrent first-trimester or second-trimester spontaneous miscarriage, who visited the fertility centers in Taiwan from 2011 to 2014, and one of the partners, carries a balanced structural chromosomal anomaly. After discussing with the doctor and genetics counselor, couples underwent in vitro fertilization (IVF), and a total of 365 embryos in 76 IVF cycles were biopsied for preimplantation genetic diagnosis (PGD) by array comparative genome hybridization (array CGH) screening. PART 2 Carrier screening for spinal muscular atrophy A prospective large population-based cohort study of 139,404 pregnancies was investigated in 25 counties of Taiwan during a 10 year period, 2005 through 2014. Two different validated platforms were used for parallel SMN1/SMN2 gene quantification: denaturing high-performance liquid chromatography (DHPLC) and multiplex ligation-dependent probe amplification (MLPA). A three-stage screening program was used: (1) pregnancies were tested for SMA heterozygosity, (2) if a pregnancy was heterozygous for SMA (carrier status), the paternal partner was then tested, and (3) if both partners were SMA carriers, a prenatal diagnosis was offered. PART 3 Preimplantation genetic diagnosis for spinal muscular atrophy In this part, we report data to identify the SMN1 gene deletion on eighteen clinical embryos obtained from one participating couple, where both partners are heterozygous SMA carriers with 1-SMN1/3-SMN2 genotype. We validated and applied protocol clinically for PGD through the use of blastocyst biopsy, whole genome amplification, mini-sequencing genotype coupling with genetic linkage of SMN gene involving three informative microsatellite markers, and thawed embryo transfer. PART 4 Newborn genetic screening for hereditary hearing impairment This is a prospective population-based cohort study of 26,764 newborns in Taiwan conducted during the period 2011 to 2014. Based on Taiwanese genetic database of hereditary hearing impairment, the newborn genetic screening targeted four deafness-associated mutations commonly found in the Taiwanese population, including c.109G>A of the GJB2 gene, c.235delC of the GJB2 gene, c.919-2A>G of the SLC26A4 gene, and mitochondrial m.1555A>G of the 12S rRNA gene. The newborn genetic screening were performed using polymerase chain reaction (PCR) assay with fluorescence resonance energy transfer (FRET) hybridization probes in a real-time PCR detection system. Results PART 1 Preimplantation genetic diagnosis for chromosomal translocation A total of 365 embryos from 76 cycles were analyzed, and the overall diagnostic efficiency was 89.04% (325/365). Then 315 embryos were analyzed by aCGH, as well as the euploidy rate and aneuploidy rate were 26.67% (84/315) and 73.33% (231/315), respectively. 49 cycles of thawed embryo transfer (ET) were carried out, and the average transfer embryo was 1.11 pieces. According our record for 52 IVF cycles of 32 couples, there were 15 women got pregnant and pregnancy rate per cycle was 28.85% (15/52). PART 2 Carrier screening for spinal muscular atrophy We found 2,859 individuals with one copy of the SMN1 genotype, recognized to be SMA carriers, among the 139,404 pregnancies screened. The carrier rate in our population was approximately 1 in 49 (2.05%). Of these individuals, 58 couples were at high risk for having offspring with SMA after testing of partners or spouses 2,504 who were also determined to be SMA carriers. Prenatal diagnoses were determined for 49 pregnancies (84.48%), of which 13 (26.53%) fetuses were diagnosed with SMA; the prevalence of SMA in our population was 1 in 10,723. PART 3 Preimplantation genetic diagnosis for spinal muscular atrophy Approximately 77.78% (14/18) of blastocysts were successfully amplified in a single PGD cycle. Among these embryos, ten (72%, 10/14) were diagnosed as unaffected, two (14%, 2/14) as affected, and two embryos (14%, 2/14) had no conclusive diagnosis due to allele drop-out (ADO). Two unaffected embryos were thawed and transferred in the next cycle resulting in a singleton pregnancy, and the birth of a healthy girl who carries the 1-SMN1/3-SMN2 genotype. PART 4 Newborn genetic screening for hereditary hearing impairment Of the 26,764 newborns, a total of 5,253 (19.63%) babies were found to have at least 1 mutated allele on the newborn genetic screening for hearing impairment. A total of 399 newborns (1.49%) carrier either homozygous, compound heterozygous or homoplasmic mutations in targeted gene, who may potentially have hearing loss. 293 (1.11%) of whom were homozygous for GJB2 c.109 G>A, 2 (0.01%) were homozygous for GJB2 c.235delG, 5 (0.02%) were homozygous for SLC26A4 c.919-2A>G, 28 (0.11%) compound heterozygous for GJB2 c.109 G>A and c.235delC, and 66 (0.25%) homoplasmic or heteroplasmic for m.1555A>G in 12SrRNA gene. Conclusion Here we established four novel genetic testing platforms, including PGD for chromosomal translocation, carrier screening for SMA, PGD for single gene disorder and newborn genetic screening for hereditary hearing impairment. With constantly improved technology and drastically reduced cost, genetic testing can be a powerful tool for achieving molecular diagnosis. We hope the application to clinical can help more and more patients and families. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T02:26:21Z (GMT). No. of bitstreams: 1 ntu-104-D98455001-1.pdf: 11124993 bytes, checksum: 01f5fcd212858d00378e74a7174af0c7 (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | Table of Contents
口試委員會審定書----------------------------------------------------------------------------Ⅰ 誌謝----------------------------------------------------------------------------------------------Ⅱ 中文摘要----------------------------------------------------------------------------------------Ⅲ Abstract-----------------------------------------------------------------------------------------Ⅵ List of Figures-------------------------------------------------------------------------------ⅩⅤ List of Tables--------------------------------------------------------------------------------ⅩⅥ PART 1 Preimplantation genetic diagnosis (PGD) for chromosomal translocation---------1 Abstract--------------------------------------------------------------------------------------------2 1.1 Introduction-----------------------------------------------------------------------------------3 1.2 Materials and Methods---------------------------------------------------------------------6 1.2.1 Study population----------------------------------------------------------------------6 1.2.2 Blastocyst biopsy and cryopreservation of biopsied embryos------------------6 1.2.3 Whole genome amplification and aCGH------------------------------------------7 1.2.4 Thawed ET-----------------------------------------------------------------------------7 1.2.5 Confirmation of karyotype of fetus with conventional prenatal diagnosis----8 1.2.6 Statistical analyses--------------------------------------------------------------------8 1.3 Results-----------------------------------------------------------------------------------------9 1.4 Discussions----------------------------------------------------------------------------------11 PART 2 Carrier screening for inherited genetic disorder----------------------------------------15 Abstract------------------------------------------------------------------------------------------16 2.1 Introduction---------------------------------------------------------------------------------18 2.2 Materials and Methods--------------------------------------------------------------------21 2.2.1 Sample Collection-------------------------------------------------------------------21 2.2.2 Three-stage Screening--------------------------------------------------------------21 2.2.3 Genetic Counseling-----------------------------------------------------------------22 2.2.4 DNA extraction----------------------------------------------------------------------23 2.2.5 Multiplex Polymerase Chain Reaction and DHPLC Analysis-----------------23 2.2.6 Multiplex Ligation-dependent Probe Amplifications---------------------------23 2.2.7 Classification of SMA Severity-----------------------------------------------------24 2.2.8 Statistical Analysis------------------------------------------------------------------24 2.2.9 Cost Benefit Analysis----------------------------------------------------------------24 2.3 Results---------------------------------------------------------------------------------------26 2.3.1 First-stage Prescreening------------------------------------------------------------26 2.3.2 Second-Stage Prescreening Results-----------------------------------------------26 2.3.3 Third-Stage Prescreening Results-------------------------------------------------27 2.3.4 Cost Analysis of the SMA Screening Program-----------------------------------28 2.4 Discussion-----------------------------------------------------------------------------------30 PART 3 Preimplantation genetic diagnosis (PGD) for single gene disorder-----------------34 Abstract------------------------------------------------------------------------------------------35 3.1 Introduction---------------------------------------------------------------------------------36 3.2 Materials and Methods--------------------------------------------------------------------38 3.2.1 Clinical data-------------------------------------------------------------------------38 3.2.2 Genetic counseling before and after PGD --------------------------------------38 3.2.3 Single lymphocyte testing-----------------------------------------------------------38 3.2.4 In vitro fertilization and blastocyst biopsy---------------------------------------39 3.2.5 Vitrification of blastocysts----------------------------------------------------------39 3.2.6 Whole genome amplification (WGA)---------------------------------------------39 3.2.7 Mini-sequencing---------------------------------------------------------------------40 3.2.8 Linkage analysis by short tandem repeat (STR) markers----------------------40 3.2.9 Thawed embryo transfer------------------------------------------------------------41 3.3 Results---------------------------------------------------------------------------------------42 3.3.1 Assay optimization------------------------------------------------------------------42 3.3.2 Validation of protocol from single lymphocyte----------------------------------43 3.3.3 Mutation analysis in trophoblast cells--------------------------------------------43 3.3.4 Embryo transfer and follow-up of pregnancy-----------------------------------44 3.4 Discussion-----------------------------------------------------------------------------------45 PART 4 Newborn genetic screening------------------------------------------------------------------48 Abstract------------------------------------------------------------------------------------------49 4.1 Introduction---------------------------------------------------------------------------------51 4.2 Materials and Methods--------------------------------------------------------------------53 4.2.1 Recruitment and study design------------------------------------------------------53 4.2.2 Newborn hearing screening--------------------------------------------------------53 4.2.3 Newborn genetic screening for deafness-----------------------------------------54 4.2.4 Audiological assessments after discharge----------------------------------------55 4.2.5 Genetic examination in hearing impaired infants-------------------------------55 4.3 Results---------------------------------------------------------------------------------------57 4.3.1 Results of newborn hearing screening--------------------------------------------57 4.3.2 Results of newborn genetic screening for deafness-----------------------------57 4.3.3 Analysis of NHS results according to genotypes in NGS-----------------------58 4.3.4 Audiological assessments after discharge----------------------------------------59 4.4 Discussion-----------------------------------------------------------------------------------60 PART 5 Future perspective----------------------------------------------------------------------------68 5.1 Non-invasive prenatal screening plus (NIPS+) for fetal trisomy 2 and trisomy 5 mosaicism cases---------------------------------------------------------------------------69 5.2. Non-invasive prenatal screening plus (NIPS+): Detection of fetal 22q11.2 microdeletion and microduplcation syndromes---------------------------------------70 5.3 Targeted next-generation sequencing panel for detection of mutations in hearing impairment------------------------------------------------------------------------71 5.4 Personalized cancer mutation panel by next generation sequencing for cancer prediction-----------------------------------------------------------------------------------72 References---------------------------------------------------------------------------------------73 Appendix--------------------------------------------------------------------------------------126 Curriculum Vitae--------------------------------------------------------------------------127 List of Publication------------------------------------------------------------------------128 List of Conference------------------------------------------------------------------------136 | |
dc.language.iso | en | |
dc.title | 胚胎著床前基因診斷與遺傳性疾病帶因者篩檢及新生兒基因檢測之臨床應用 | zh_TW |
dc.title | The clinical applications of preimplantation genetic diagnosis, carrier screening for inherited genetic disorder and newborn genetic screening | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 蘇怡寧,曾麗慧,李建南,林芯? | |
dc.subject.keyword | 胚胎著床前基因診斷,遺傳性疾病,帶因者篩檢,新生兒基因檢測,臨床應用, | zh_TW |
dc.subject.keyword | preimplantation genetic diagnosis,inherited genetic disorder,carrier testing,newborn genetic screening,clinical application, | en |
dc.relation.page | 139 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2015-08-18 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 基因體暨蛋白體醫學研究所 | zh_TW |
顯示於系所單位: | 基因體暨蛋白體醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 10.86 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。